Literature DB >> 33247343

MIP image derived from abbreviated breast MRI: potential to reduce unnecessary sub-nipple biopsies during nipple-sparing mastectomy for breast cancer.

Zhuangsheng Liu1, Xiaoping Li2, Bao Feng1,3, Changlin Li3, Yehang Chen3, Lilei Yi4, Zhiwei Li5, Ronggang Li6, Wansheng Long7.   

Abstract

OBJECTIVE: To determine the value of a maximum-intensity projection (MIP) image derived from abbreviated breast MRI for excluding occult nipple-areolar complex (NAC) involvement in patients with breast cancer.
METHODS: This prospective study included breast cancer patients with clinically normal NACs between April 2016 and May 2019. Abbreviated breast MRI was performed, and an MIP image was generated for each patient. MIP images were examined for the following features: asymmetric nipple enhancement, tumor-nipple distance (TND), tumor diameter, lesion type, location, and multifocality. Independent predictive MIP features for occult NAC involvement were identified by univariable and multivariable logistic regression analyses. Models based on independent predictive MIP features were developed, and their diagnostic performances were evaluated using ROC analysis. The utility of an MIP image for excluding occult NAC involvement was assessed by considering NPVs across patient subgroups.
RESULTS: Eight hundred forty-three patients (67 NAC-positive and 776 NAC-negative) were enrolled. On MIP images, asymmetric nipple enhancement (odds ratio, 6.098; p < 0.001) and TND (odds ratio, 0.564; p = 0.003) were independent predictors of occult NAC involvement. A parallel test model of "asymmetric nipple enhancement or TND ≤ 15 mm" yielded the highest AUC value (0.838) among prediction models. The NPV of MIP images for excluding occult NAC involvement was 99.5%, which was applicable across various patient subgroups.
CONCLUSIONS: A single MIP image derived from abbreviated breast MRI has utility for excluding occult NAC involvement in breast cancer patients and reducing the number of unnecessary sub-nipple biopsies in nipple-sparing mastectomy. KEY POINTS: • On MIP images derived from abbreviated breast MRI, asymmetric nipple enhancement and tumor-nipple distance were independent predictors for occult nipple involvement in patients with breast cancer. • Negative findings on MIP image can help select patients at minimal risk of occult nipple involvement, for whom unnecessary intraoperative sub-nipple biopsies in nipple-sparing mastectomy can be omitted.

Entities:  

Keywords:  Breast neoplasms; Magnetic resonance imaging; Mastectomy; Nipples; Predictive value of tests

Mesh:

Year:  2020        PMID: 33247343     DOI: 10.1007/s00330-020-07550-w

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  2 in total

1.  MRI diagnostic features for predicting nipple-areolar-complex involvement in breast cancer.

Authors:  Jieun Koh; Ah Young Park; Kyung Hee Ko; Hae Kyoung Jung
Journal:  Eur J Radiol       Date:  2019-11-20       Impact factor: 3.528

2.  Use of preoperative mammography, ultrasonography, and MRI to predict nipple areolar complex involvement in breast cancer.

Authors:  Soyeoun Lim; Gyeongmin Park; Hye-Jeong Choi; Woon Jung Kwon; Byeong Seong Kang; Minseo Bang
Journal:  Br J Radiol       Date:  2019-08-13       Impact factor: 3.039

  2 in total
  2 in total

1.  COVID-19 safety measures at the Radiology Unit of a Transplant Institute: the non-COVID-19 patient's confidence with safety procedures.

Authors:  Roberta Gerasia; Giuseppe Mamone; Santina Amato; Antonino Cucchiara; Giuseppe Salvatore Gallo; Corrado Tafaro; Giuseppe Fiorello; Calogero Caruso; Roberto Miraglia
Journal:  Radiol Med       Date:  2022-03-13       Impact factor: 6.313

2.  Predicting lymphovascular invasion in clinically node-negative breast cancer detected by abbreviated magnetic resonance imaging: Transfer learning vs. radiomics.

Authors:  Bao Feng; Zhuangsheng Liu; Yu Liu; Yehang Chen; Haoyang Zhou; Enming Cui; Xiaoping Li; Xiangmeng Chen; Ronggang Li; Tianyou Yu; Ling Zhang; Wansheng Long
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.